European Journal of Rheumatology
Case-Based Review

Ruxolitinib for Refractory Macrophage Activation Syndrome Complicating Adult-Onset Still’s Disease


Shamir Medical Center, Internal Medicine B, Rheumatology Unit, Zerifin, Israel


Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel


Shamir Medical Center, Department of Hematology, Zerifin, Israel


Shamir Medical Center, Internal Medicine B, Zerifin, Israel


Sheba Medical Center, Center for Autoimmune Diseases, Clinical Immunology, Angioedema and Allergy Unit, Tel-Hashomer, Israel

Eur J Rheumatol 2022; 9: 217-220
DOI: 10.5152/eurjrheum.2022.21064
Read: 1259 Downloads: 375 Published: 04 July 2022

Macrophage activation syndrome is the most frequent life-threatening complication of adult-onset Still’s disease. This is a nearly fatal case of a young patient, which has been refractory to corticoste- roids, anakinra, tocilizumab, cyclosporine A, and etoposide, but eventually responded miraculously to salvage therapy with ruxolitinib. We review recent pertinent data related to the therapeutic value of ruxolitinib for macrophage activation syndrome triggered by adult-onset Still’s disease.

Cite this article as: Levy O, Apel A, Alhdor H, et al. Ruxolitinib for refractory macrophage activation syndrome complicating adult-onset still’s disease. Eur J Rheumatol. 2022;9(4):217-220.

EISSN 2148-4279